Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Victor H Jimenez Zepeda, MD, Suzanne Trudel, MD, MSC, FRCPC, Donna E. Reece, MD, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Norman Franke, MD, Andrew Winter, Sr., RN, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 3396.

https://doi.org/10.1182/blood.V122.21.3396.3396

Published: 2013

Journal Articles

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

Sophia Farooki, MD, FRCPC, Manjula Maganti, Donna E Reece, MD, FRCPC, Esther Masih-Khan, PhD, Victor H Jimenez-Zepeda, MD, PD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5315.

https://doi.org/10.1182/blood.V122.21.5315.5315

Published: 2013

Journal Articles

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Blood (2013) 122 (21): 4352.

https://doi.org/10.1182/blood.V122.21.4352.4352

Published: 2013

Journal Articles

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Victor H Jimenez Zepeda, MD, Donna E. Reece, MD, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD PhD FRACP, FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2013) 122 (21): 5398.

https://doi.org/10.1182/blood.V122.21.5398.5398

Published: 2013

Journal Articles

Absolute Lymphocyte Count At Day+15 and +30 Post-ASCT As Predictors of Early and 1-Year Mortality for Patients with AL Amyloidosis Treated with a Single Autologous Stem Cell Transplant

Victor Hugo Jimenez-Zepeda, MD PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4518.

https://doi.org/10.1182/blood.V120.21.4518.4518

Published: 2012

Journal Articles

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Victor H Jimenez-Zepeda, MD, PD, Donna Reece, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD, FRACP, FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 4064.

https://doi.org/10.1182/blood.V120.21.4064.4064

Published: 2012

Journal Articles

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

Victor Hugo Jimenez-Zepeda, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Suzanne Trudel, MD, MSC, FRCPC, Christine I. Chen, MD, Rodger E. Tiedemann, MD, PhD FRACP FRCPA, Vishal Kukreti, MD

Blood (2012) 120 (21): 595.

https://doi.org/10.1182/blood.V120.21.595.595

Published: 2012

Journal Articles

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Donna E. Reece, MD, FRCPC, Giovanni Piza Rodriguez, MD, David Szwajcer, MD, FRCPC, Leonard A Minuk, MD, FRCPC, Mariela Pantoja, MSc, PhD, Andrew Belch, MD, Chaim Shustik, MD, Julie Stakiw, MD, Darrell J. White, MD, Christine Chen, MD, MSC, FRCPC, Vishal Kukreti, MD, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Michael Sebag, MD, PhD, Gayle Jenkins, Nizar J Bahlis, MD, Lisa W Le, MSc, Suzanne Trudel, MD

Blood (2011) 118 (21): 3982.

https://doi.org/10.1182/blood.V118.21.3982.3982

Published: 2011

Journal Articles

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

Christine Chen, MD, MEd, FRCPC, Ahmed M. Rabea, MD, Esther Masih-Khan, PhD, Chia-Min Chu, Vishal Kukreti, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Donna E. Reece, MD, FRCPC

Blood (2011) 118 (21): 3983.

https://doi.org/10.1182/blood.V118.21.3983.3983

Published: 2011

Journal Articles

ERN1/IRE1 and XBP1 Are Dispensable for Myeloma Cell Survival but Are Required for the Anti-Myeloma Activity of Bortezomib

Chungyee Leung-Hagesteijn, MSc, Brad Wouters, PhD, Rodger E. Tiedemann, MD PhD FRACP FRCPA

Blood (2011) 118 (21): 986.

https://doi.org/10.1182/blood.V118.21.986.986

Published: 2011

Journal Articles

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Norman Franke, MD, Andrew Winter, Sr., RN, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4121.

https://doi.org/10.1182/blood.V118.21.4121.4121

Published: 2011

Journal Articles

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

Victor H Jimenez-Zepeda, MD, PD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Christine Chen, MD, Andrew Winter, Sr., RN, Norman Franke, MD, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 4111.

https://doi.org/10.1182/blood.V118.21.4111.4111

Published: 2011

Journal Articles

CYBOR-D Induction Therapy In Clinical Practice

Christine Chen, MD, Esther Masih-Khan, PhD, Victor Jimenez-Zepeda, MD, Donna E. Reece, MD, FRCPC, Suzanne Trudel, MD, MSC, FRCPC, Rodger E. Tiedemann, MD PhD FRACP FRCPA, Vishal Kukreti, MD, FRCPC

Blood (2011) 118 (21): 5136.

https://doi.org/10.1182/blood.V118.21.5136.5136

Published: 2011

NARROW

Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents

Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

Absolute Lymphocyte Count At Day+15 and +30 Post-ASCT As Predictors of Early and 1-Year Mortality for Patients with AL Amyloidosis Treated with a Single Autologous Stem Cell Transplant

Botezomib Containing Regimens Provide a Rapid Hematological and Cardiac Response in Patients with AL Amyloidosis

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,

Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) – Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),

ERN1/IRE1 and XBP1 Are Dispensable for Myeloma Cell Survival but Are Required for the Anti-Myeloma Activity of Bortezomib

Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,

Very Good Partial Response and Complete Response Predict Superior Overall Survival and Progression Free Survival After Single Autologous Stem Cell Transplant in Patients with Multiple Myeloma,

CYBOR-D Induction Therapy In Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only